Liquidity (Narrative) (Details) - USD ($)		12 Months Ended
	Jan. 12, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and cash equivalents		$ 5,132,000	$ 5,711,000	$ 9,370,000
Liquidity, management evaluation		On January 12, 2018, the Company completed a registered public offering of common stock resulting in net proceeds to the Company of approximately $3.5 million (see Note 14). Management made operational changes in 2017 that have reduced cash expenditures and supported the Company's strategic emphasis on precisely targeted bacteriophage therapies. Considering the Company's current cash resources, including the net proceeds from the public offering in January 2018, management believes the Company's existing resources will be sufficient to fund the Company's planned operations into the third quarter of 2018.
Subsequent Event [Member]
Proceeds from issuance of common stock	$ 3,500,000